

Pharmacy Formulary Updates for February 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in February 2021:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Fosfomycin tromethamine	Tier 2
Samsca® 30 mg	NC
Vumerity®	Tier 2; SP
rufinamide 40mg/mL suspension	Tier 2; QL
norethindrone acetate-ethinyl estradiol-FE	T1; ACA
Qdolo (tramadol hcl)	NC; QL
Impeklo™ (clobetasol propionate)	NC
Mycapssa®	Tier 3; PA
Kesimpta® (ofatumumab)	Tier 2; SP
Reditrex™ (methotrexate)	NC
Conjupri® (levamlodipine maleate)	NC
CGM Receiver	Excluded
CGM Transmitter	Excluded
CGM Sensor Pack	Excluded

Key:

- MB:** Medical Benefit
- NC:** Not covered
- NTM:** New-to-market
- PA:** Prior Authorization
- QL:** Quantity Limitation
- SP:** Specialty Pharmacy - provided through CVS/specialty
- ST:** Step Therapy